Why cagrilintide alone is discussed so much less than in combination — does this still hold?

Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.

Cagrilintide alone: setting out the arithmetic in full, because I have had to do it twice and I would rather nobody else did.

Every step is shown. If the answer is wrong the error will be visible, which is the point of writing it out rather than posting the result.

Post #2 and I disagree about the size of the effect, not about the direction.

Cagrilintide alone came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.

I looked this up rather than remembered it, which is the right order.

Post #21 describes the usual case. This is about the unusual one.

The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.

I would rather say I do not know than round it up to an answer.